Non-exclusive Drug Discount Agreement for Liraglutid
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Liraglutid (ATC-Code nach WHO: A10BJ02; amtlicher ATC: A10BJ02)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum purchase quantities; actual demand depends on unpredictable factors (prescriptions, pharmacy behavior). Reve...
Buyer reserves the right to terminate the open-house process early if exclusive agreements are concluded (typical 8-12...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jun 30, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2027
- Conclusion of non-exclusive discount agreements for the supply of Liraglutid (ATC A10BJ02) to the AOK PLUS health insurance.
- Open-house model: all qualified pharmaceutical companies can participate at any time during the participation period.
Show full summary
Non-exclusive drug discount agreement for the active substance Liraglutid (ATC A10BJ02) under German social law (§ 130a Abs. 8 SGB V), using an open-house model. The agreement is open to all qualified pharmaceutical companies, with no exclusivity. No estimated value or guaranteed purchase quantities are provided. The agreement ends on 30 June 2027.
Risks
No minimum purchase quantities; actual demand depends on unpredictable factors (prescriptions, pharmacy behavior). Reve...
Buyer reserves the right to terminate the open-house process early if exclusive agreements are concluded (typical 8-12...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company as defined in § 4 Abs. 18 AMG with respect to the offered product.
- Company seat must be in Germany, EU, or EEA.
Eligibility
- Submit required declarations (exclusion grounds, Russia sanctions).
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive Drug Discount Agreement for Liraglutid
Open-house model for concluding non-exclusive discount agreements on pharmaceuticals containing Liraglutid (ATC A10BJ02). No guaranteed volumes, no exclusivity. Multiple submissions possible during the participation period.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Liraglutid (ATC-Code nach WHO: A10BJ02; amtlicher ATC: A10BJ02)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 05 May 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 309108-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum purchase quantities; actual demand depends on unpredictable factors (prescriptions, pharmacy behavior). Reve...
Buyer reserves the right to terminate the open-house process early if exclusive agreements are concluded (typical 8-12...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications